Product Reports Resources Pricing Login Book a demo

Shanghai Fosun Pharmaceutical

Biotech & Life Sciences · Baoshan District, China · Founded 1994 · IPO 2012

Shanghai Fosun Pharmaceutical a leading healthcare company in China

Valuation $11B
Revenue $5.96B
EBITDA $946M

Global footprint

Where Shanghai Fosun Pharmaceutical has talent and traffic

Workforce by country
25 countries with
team presence
🇨🇳 China82.5%
🇺🇸 United States5.1%
🇭🇰 Hong Kong2.5%
🇬🇧 United Kingdom1.6%
🇮🇳 India1.2%
Top 5 of 25 shown
Web traffic by country
28K monthly visits
across markets
🇨🇳 China53.2%
🇺🇸 United States10.4%
🇭🇰 Hong Kong8.2%
🏳️ Korea5.4%
🏳️ Republic of5.4%
Top 5 markets shown

Talent graph

The shape of Shanghai Fosun Pharmaceutical's talent

Dealroom maps Shanghai Fosun Pharmaceutical's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Shanghai Fosun Pharmaceutical's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$166M patent portfolio · 1,781 active families

Estimated portfolio value
$166M
1.5% of market cap · 7.9× larger than top peer ChemoMetec ($21M)
1,781 active patent families
Where Shanghai Fosun Pharmaceutical innovates Analytical chemistryBiomedical engineeringChemistryMechanical engineeringMedicinal chemistry

Where Shanghai Fosun Pharmaceutical concentrates vs peers

Each axis is a top-10 topic across Shanghai Fosun Pharmaceutical and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Shanghai Fosun Pharmaceutical's 27 investments and acquisitions.

Every disclosed deal where Shanghai Fosun Pharmaceutical appeared as a backer or acquirer, 2009–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

27 deals across Shanghai Fosun Pharmaceutical's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Shanghai Fosun Pharmaceutical deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Shanghai Fosun Pharmaceutical's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        27 of 27 deals

        Market sentiment

        What the market is saying about Shanghai Fosun Pharmaceutical

        An AI-synthesized read of the highest-engagement posts about Shanghai Fosun Pharmaceutical on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Shanghai Fosun Pharmaceutical on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.